What's in Xian-Janssen Pharmaceutical Ltd.'s pipeline?

Xian-Janssen Pharmaceutical Ltd. has 7 drugs in our index: 5 marketed, 0 filed, 2 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Xian-Janssen Pharmaceutical Ltd.'s portfolio?

Top competitors by shared drug class: University of Rochester, Ahmed M Maged, MD, Barrie Urology Associates, Albert Einstein College of Medicine, Amsterdam UMC, location VUmc.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/xian-janssen-pharmaceutical-ltd.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Xian-Janssen Pharmaceutical Ltd. — Portfolio Competitive Intelligence Brief

Xian-Janssen Pharmaceutical Ltd. pipeline: 5 marketed, 0 filed, 2 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

5 marketed 0 filed 2 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Galantamine oral solution	Galantamine oral solution	marketed
Carraghenates Cream	Carraghenates Cream	marketed
Polyethylene glycol (PEG)	Polyethylene glycol (PEG)	marketed	Osmotic laxative		Gastroenterology
Tramadol HCl-Paracetamol	Tramadol HCl-Paracetamol	marketed	Opioid analgesic combination	Opioid receptors (μ, δ, κ); monoamine transporters (norepinephrine, serotonin); cyclooxygenase enzymes	Pain Management
Mayinglong Musk Hemorrhoid Ointment	Mayinglong Musk Hemorrhoid Ointment	marketed
ER OROS paliperidone and Olanzapine	ER OROS paliperidone and Olanzapine	phase 3	Atypical antipsychotic combination	Dopamine D2 receptor, Serotonin 5-HT2A receptor	Psychiatry / Neurology
Loperamide hydrochloride + simethicone chewable tablet	Loperamide hydrochloride + simethicone chewable tablet	phase 3	Antidiarrheal and antifoaming agent	μ-opioid receptors, gas bubbles	Gastroenterology

Therapeutic area mix

Gastroenterology · 2
Pain Management · 1
Psychiatry / Neurology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

University of Rochester · 2 shared drug classes
Ahmed M Maged, MD · 1 shared drug class
Barrie Urology Associates · 1 shared drug class
Albert Einstein College of Medicine · 1 shared drug class
Amsterdam UMC, location VUmc · 1 shared drug class
Azienda Policlinico Umberto I · 1 shared drug class
Albany Medical College · 1 shared drug class
Aboca Spa Societa' Agricola · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Xian-Janssen Pharmaceutical Ltd.:

Cite this brief

Drug Landscape (2026). Xian-Janssen Pharmaceutical Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/xian-janssen-pharmaceutical-ltd. Accessed 2026-05-16.